PMID- 17586782
OWN - NLM
STAT- MEDLINE
DCOM- 20070823
LR  - 20151119
IS  - 1064-7481 (Print)
IS  - 1064-7481 (Linking)
VI  - 15
IP  - 7
DP  - 2007 Jul
TI  - Suicidal thinking and behavior during treatment with sertraline in late-life 
      depression.
PG  - 573-80
AB  - OBJECTIVE: To determine effects of sertraline on suicidal thinking and behavior 
      in patients with late-life major depression. METHODS: This was a secondary 
      analysis of an eight-week, placebo-controlled, double-blind randomized trial of a 
      multicenter trial at 66 clinical sites. Outpatients >/=60 years of age with major 
      depression and a Hamilton Depression Rating (HAMD) score >/=18 were included. 
      Intervention was sertraline 50-100 mg/day or placebo for eight weeks. 
      Measurements were 17-item HAMD administered at baseline and two-week intervals. 
      HAMD Item 3 used to assess suicidal ideation (SI) and behavior. Reports of 
      serious adverse events (SAEs), adverse events (AEs) leading to discontinuation, 
      and spontaneously reported adverse events reviewed. RESULTS: A total of 747 
      patients received at least one dose of medication, and 728 had at least one 
      posttreatment assessment. Mean age (+/-SD) was 69.8 +/- 6.7 years (range: 59-97 
      years) and 56% were female. There were no completed suicides or suicide attempts 
      during the double-blind trial. One SAE, hospitalization, was associated with SI 
      in a patient on sertraline. No other AEs were associated with SI or behavior. 
      HAMD Item 3 ratings progressively declined during the trial with significantly 
      lower values for sertraline than placebo (Z = 2.41, p <0.02). In 248 patients 
      with HAMD Item 3 of zero at baseline, the percentage of patients whose Item 3 
      ratings increased during treatment did not differ in the two groups (22.4% versus 
      25.8% for sertraline and placebo, respectively.) CONCLUSION: Sertraline was 
      associated with significantly lower HAMD Item 3 scores than placebo during 
      treatment. There was no evidence of greater emergent suicidal thinking or 
      behavior with sertraline than placebo.
FAU - Nelson, J Craig
AU  - Nelson JC
AD  - Department of Psychiatry, University of California San Francisco, San Franciso, 
      CA, USA. craign@lppi.ucsf.edu
FAU - Delucchi, Kevin
AU  - Delucchi K
FAU - Schneider, Lon
AU  - Schneider L
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Am J Geriatr Psychiatry
JT  - The American journal of geriatric psychiatry : official journal of the American 
      Association for Geriatric Psychiatry
JID - 9309609
RN  - 0 (Antidepressive Agents)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antidepressive Agents/adverse effects/*therapeutic use
MH  - Depressive Disorder, Major/diagnosis/*epidemiology/*psychology
MH  - Double-Blind Method
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sertraline/adverse effects/*therapeutic use
MH  - Severity of Illness Index
MH  - Suicide, Attempted/prevention & control/*psychology/*statistics & numerical data
MH  - Surveys and Questionnaires
MH  - *Thinking
EDAT- 2007/06/26 09:00
MHDA- 2007/08/24 09:00
CRDT- 2007/06/26 09:00
PHST- 2007/06/26 09:00 [pubmed]
PHST- 2007/08/24 09:00 [medline]
PHST- 2007/06/26 09:00 [entrez]
AID - 15/7/573 [pii]
AID - 10.1097/JGP.0b013e318050c9c2 [doi]
PST - ppublish
SO  - Am J Geriatr Psychiatry. 2007 Jul;15(7):573-80. doi: 
      10.1097/JGP.0b013e318050c9c2.